Xspray Pharma

26.65 SEK

-0.93 %

Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-0.93 %

-0.16 %

+10.28 %

-12.86 %

+4.60 %

-15.83 %

-50.87 %

-68.32 %

-9.26 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Market cap

1.26B SEK

Turnover

1.55M SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.5

2026

General meeting '26

5.8

2026

Interim report Q2'26

5.11

2026

Interim report Q3'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press releaseyesterday

New number of shares and votes in Xspray Pharma after new share issue April 2026

Regulatory press release4/28/2026, 6:00 AM

Interim Report First Quarter 2026

Third party research4/24/2026, 6:48 AM

Xspray Pharma: Summer PDUFA dates put launch within reach - Edison

Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer. The oversubscribed rights issue (securing SEK113m in gross proceeds) will remove the principal financing overhang, and any future financing needs are ...

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/23/2026, 6:00 AM

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

Press release4/14/2026, 2:10 PM

FDA accepts trade name Nilopki® for Xspray's drug candidate XS003 (nilotinib)

Regulatory press release4/9/2026, 6:00 AM

Notice of annual general meeting of Xspray Pharma AB (publ)

Regulatory press release3/31/2026, 6:15 AM

Xspray publishes disclosure document regarding rights issue

Press release3/26/2026, 2:55 PM

Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased

Regulatory press release3/26/2026, 7:00 AM

Xspray Pharma publishes its Annual Report 2025

Regulatory press release3/24/2026, 8:40 PM

Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue

Press release3/11/2026, 2:50 PM

Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026

Press release2/26/2026, 2:59 PM

Xspray Pharma re-submits its FDA application for Dasynoc

Regulatory press release2/26/2026, 6:45 AM

Xspray Pharma appoints Blake Leitch as CEO – Per Andersson continues as Chief Scientific Officer (CSO)

Press release2/17/2026, 7:26 AM

Redeye: Xspray Pharma (Q4 Review): A pivotal year ahead

Regulatory press release2/12/2026, 7:00 AM

Interim Report Fourth Quarter 2025

Press release11/7/2025, 7:52 AM

Redeye: Xspray Pharm (Q3 update) - Two PDUFA dates in 2026

Regulatory press release11/5/2025, 7:00 AM

Interim Report Third Quarter 2025

Press release10/21/2025, 9:45 AM

Xspray Pharma: FDA accepts New Drug Application for XS003 (nilotinib) for the treatment of CML – PDUFA date set for June 18, 2026

Press release10/19/2025, 2:43 PM

Redeye: Xspray Pharma - Update after Dasynoc CRL

Regulatory press release10/10/2025, 8:00 AM

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.